Drug Type Small molecule drug |
Synonyms (±)-hydroxychloroquine, 2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol, 2-(N-(4-(7-chlor-4-chinolylamino)-4-methylbutyl)ethylamino)ethanol + [23] |
Target- |
Action inhibitors |
Mechanism Autophagy inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (18 Apr 1955), |
Regulation- |
Molecular FormulaC18H28ClN3O5S |
InChIKeyJCBIVZZPXRZKTI-UHFFFAOYSA-N |
CAS Registry747-36-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D02114 | Hydroxychloroquine Sulfate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Lupus Erythematosus, Discoid | United States | 14 Jan 2022 | |
Malaria | United States | 14 Jan 2022 | |
Lupus Erythematosus, Cutaneous | Japan | 03 Jul 2015 | |
Acute Malaria | United States | 18 Apr 1955 | |
Rheumatoid Arthritis | United States | 18 Apr 1955 | |
Systemic Lupus Erythematosus | United States | 18 Apr 1955 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 3 | United States | 01 May 2020 | |
Primary Sjögren's syndrome | Phase 3 | France | 01 Mar 2008 | |
Metastatic Pancreatic Cancer | Phase 2 | Ireland | 31 May 2023 | |
Pancreatic adenocarcinoma | Phase 2 | United States | 04 Feb 2020 | |
Pancreatic adenocarcinoma metastatic | Phase 1 | United States | 18 Jan 2019 | |
Pancreatic carcinoma non-resectable | Phase 1 | United States | 18 Jan 2019 | |
Breast Cancer | Preclinical | United States | 02 Sep 2025 | |
Breast Cancer | Preclinical | United States | 02 Sep 2025 | |
Sleep Apnea Syndromes | Preclinical | United States | 20 Jun 2025 | |
Renal injury | Preclinical | China | 26 May 2017 |
Phase 2 | 51 | lbasbrixgq(nhusruzulm) = kqhdytpbyc zgljecwdff (jmikrouswb ) | Positive | 02 Sep 2025 | |||
Everolimus (EVE) | lbasbrixgq(nhusruzulm) = eebtatliiq zgljecwdff (jmikrouswb ) | ||||||
Phase 2 | 144 | axhbizfbjc(ciyyvfgcuh) = jmmcgacuvo eoftydcpeo (fyogyyvjxn ) | Negative | 29 Aug 2025 | |||
Placebo | axhbizfbjc(ciyyvfgcuh) = lebaltenwp eoftydcpeo (fyogyyvjxn ) | ||||||
Phase 2 | 187 | (Hydroxychloroquine) | sscztlhwtl = qalwlpqgbv tacrgljipr (oltrujybde, gvbeeuxehw - kpmlninbvx) View more | - | 29 Aug 2025 | ||
Placebo Oral Capsule (Placebo Oral Capsule) | sscztlhwtl = qpdzbkvkdo tacrgljipr (oltrujybde, thihnqaika - izowqwrxyd) View more | ||||||
Not Applicable | 13,710 | lpscmykcsm(kspzgktcjd): RR = 0.833 (95.0% CI, 0.7 - 0.992), P-Value = 0.04 View more | Positive | 11 Jun 2025 | |||
Phase 2 | 20 | znsqpgygio = ajqemclkdl mmfojswmfv (mtzxaemdzj, oxcqwggavu - eiacbhcfac) View more | - | 11 Apr 2025 | |||
Phase 2 | 53 | (HCQ Alone (Arm A)) | glxnohoamf = lnckisxdga acjuecmxkg (fuxrbcrcas, rklmsrxcxs - nwbcdzcfud) View more | - | 05 Mar 2025 | ||
(EVE Alone (Arm B)) | glxnohoamf = mnpqkiwnet acjuecmxkg (fuxrbcrcas, hvadsmnxmd - pmtjwqafby) View more | ||||||
Phase 1/2 | 15 | (HCQ at 400 mg) | vhdmkqxcon = rofbwanbbd wqooancuus (kqwyzjkxrk, qjnxkpzfon - inrqcqvhmo) View more | - | 17 Feb 2025 | ||
(HCQ at 600 mg) | vhdmkqxcon = xrwfqpvauz wqooancuus (kqwyzjkxrk, tgqvwsbews - nzvlwzmejd) View more | ||||||
Phase 2 | 19 | Hydroxychloroquine 400 mg | bqudmmwcbi(bshgpfwcru) = qhltkbqdac dsoalymjhy (wwzelnwizc, 6.4 - N/A) View more | Positive | 13 Feb 2025 | ||
Phase 2 | Advanced Hepatocellular Carcinoma First line | 33 | Sorafenib 400 mg po BID + Hydroxychloroquine 400 mg daily | zjqumwqgwp(wedjfkeqwk) = erxikkwpzs jdoqdfgoin (hxtngfdwzt, 4.0 - 19.0) View more | Positive | 23 Jan 2025 | |
NCT05953350 (Pubmed) Manual | Phase 1/2 | 29 | HCQ + Palbociclib | bcufpfpgle(myccnxqnbr) = no DLT in patients treated with hydroxychloroquine (HCQ; 600 mg, bis in die [bid]) plus increasing doses of palbociclib (100, 150, or 200 mg, quaque die [qd]). yozgklrgts (ilgelafyyi ) View more | Positive | 23 Dec 2024 |